Met Life Investment Management, LLC Eagle Pharmaceuticals, Inc. Transaction History

Met Life Investment Management, LLC

$17.1 Billion
Q3 2024

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Apr 29, 2024	BUY	$17.74 - $31.87 $97,002 - $174,265	5,468 New	5,468 $106,000
Q1 2023 May 09, 2024	BUY	$25.06 - $34.09 $137,028 - $186,404	5,468 New	5,468 $155 Million
Q2 2022 May 10, 2024	SELL	$41.26 - $51.35 $94,774 - $117,950	-2,297 Reduced 29.58%	5,468 $242,000
Q2 2022 Mar 22, 2023	SELL	$41.26 - $51.35 $94,774 - $117,950	-2,297 Reduced 29.58%	5,468 $242,000
Q2 2022 Aug 11, 2022	SELL	$41.26 - $51.35 $94,774 - $117,950	-2,297 Reduced 29.58%	5,468 $243,000
Q1 2022 May 10, 2024	BUY	$44.58 - $52.6 $346,163 - $408,439	7,765 New	7,765 $384,000
Q1 2022 Jun 20, 2023	BUY	$44.58 - $52.6 $102,400 - $120,822	2,297 Added 42.01%	7,765 $384,000
Q1 2022 Mar 22, 2023	BUY	$44.58 - $52.6 $123,798 - $146,070	2,777 Added 55.67%	7,765 $384,000
Q1 2022 May 12, 2022	BUY	$44.58 - $52.6 $123,798 - $146,070	2,777 Added 55.67%	7,765 $384,000
Q4 2021 Jun 21, 2023	SELL	$45.82 - $56.9 $21,993 - $27,312	-480 Reduced 8.78%	4,988 $253,000
Q3 2021 Jun 21, 2023	SELL	$43.79 - $55.78 $21,019 - $26,774	-480 Reduced 8.78%	4,988 $278,000
Q2 2021 Jun 21, 2023	SELL	$36.86 - $44.5 $17,692 - $21,360	-480 Reduced 8.78%	4,988 $213,000
Q1 2021 May 17, 2024	BUY	$40.32 - $50.97 $201,116 - $254,238	4,988 New	4,988 $208,000
Q1 2021 Jun 26, 2023	SELL	$40.32 - $50.97 $19,353 - $24,465	-480 Reduced 8.78%	4,988 $208 Million
Q4 2020 Jun 22, 2023	SELL	$41.72 - $51.34 $20,025 - $24,643	-480 Reduced 8.78%	4,988 $232,000
Q3 2020 Jun 26, 2023	SELL	$37.02 - $51.28 $17,769 - $24,614	-480 Reduced 8.78%	4,988 $211,000
Q2 2020 May 24, 2024	BUY	$43.24 - $55.02 $215,681 - $274,439	4,988 New	4,988 $239 Million
Q2 2020 Jun 26, 2023	SELL	$43.24 - $55.02 $20,755 - $26,409	-480 Reduced 8.78%	4,988 $239,000
Q1 2020 Jul 12, 2023	SELL	$34.37 - $60.07 $16,497 - $28,833	-480 Reduced 8.78%	4,988 $229,000
Q4 2019 Jul 12, 2023	SELL	$54.32 - $64.31 $26,073 - $30,868	-480 Reduced 8.78%	4,988 $299,000
Q3 2019 Jul 12, 2023	SELL	$53.25 - $59.98 $25,560 - $28,790	-480 Reduced 8.78%	4,988 $282,000
Q2 2019 Jul 12, 2023	SELL	$46.61 - $58.45 $22,372 - $28,056	-480 Reduced 8.78%	4,988 $277,000
Q1 2019 Jul 13, 2023	SELL	$38.66 - $51.82 $18,556 - $24,873	-480 Reduced 8.78%	4,988 $251,000
Q4 2018 Jul 13, 2023	SELL	$36.72 - $67.73 $17,625 - $32,510	-480 Reduced 8.78%	4,988 $200,000
Q4 2018 Mar 22, 2023	SELL	$36.72 - $67.73 $101,016 - $186,325	-2,751 Reduced 35.55%	4,988 $200,000
Q4 2018 Feb 14, 2019	SELL	$36.72 - $67.73 $101,016 - $186,325	-2,751 Reduced 35.55%	4,988 $201,000
Q3 2018 Jul 13, 2023	SELL	$66.65 - $83.86 $31,992 - $40,252	-480 Reduced 8.78%	4,988 $345,000
Q3 2018 Mar 22, 2023	BUY	$66.65 - $83.86 $151,362 - $190,446	2,271 Added 41.53%	7,739 $536,000
Q3 2018 Nov 14, 2018	BUY	$66.65 - $83.86 $183,354 - $230,698	2,751 Added 55.15%	7,739 $537,000
Q2 2018 Aug 15, 2018	BUY	$51.25 - $76.62 $46,893 - $70,107	915 Added 22.47%	4,988 $377,000
Q4 2017 Feb 15, 2018	BUY	$49.6 - $60.87 $202,020 - $247,923	4,073	4,073 $218,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account